Company: BIAF
Filing Date: 2025-06-27
Form Type: POS AM
Source: 0001641172-25-016927
Chunk: 77

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-06-27
Form: POS AM
Chunk 77
---
, and be substituted for the Company, and may exercise every right and power that the Company may exercise and will assume all of its obligations under the August Investor 2024 Warrants with the same effect as if such successor entity had been named in the warrant itself. If holders of Common Stock are given a choice as to the securities, cash or property to be received in a Fundamental Transaction, then the holder shall be given the same choice as to the consideration it receives upon any exercise of the August 2024 Investor Warrants following such Fundamental Transaction. In addition, the successor entity, at the request of holders of the August 2024 Investor Warrants, will be obligated to purchase any unexercised portion of the August 2024 Investor Warrants in accordance with the terms thereof. Notwithstanding the foregoing, in the event of a Fundamental Transaction, the holders of the August 2024 Investor Warrants have the right to require the Company or a successor entity to redeem the August 2024 Investor Warrants for cash in the amount of the Black Scholes Value (as defined in the August 2024 Investor Warrants) of the unexercised portion of the August 2024 Investor Warrants concurrently with or within 30 days following the consummation of a Fundamental Transaction. However, in the event of a fundamental transaction which is not in our control, including a Fundamental Transaction not approved by the Company’s board of directors, the holders of the August 2024 Investor Warrants will only be entitled to receive from the Company or its successor entity, as of the date of consummation of such Fundamental Transaction, the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of the August 2024 Investor Warrants that is being offered and paid to the holders of Common Stock in connection with the Fundamental Transaction, whether that consideration is in the form of cash, stock or any combination of cash and stock, or whether the holders of our Common Stock are given the choice to receive alternative forms of consideration in connection with the Fundamental Transaction.

Except as otherwise provided in the August 2024 Investor Warrants or by virtue of such holder’s ownership of shares of our Common Stock, the holder of an August 2024 Investor Warrant will not have the rights or privileges of a holder of our Common Stock, including any voting rights, until the holder exercises such warrant.

The Inducement Advisor Warrants and the August 2024 PA Warrants have substantially